Esophageal cancer
Conditions
Interventions
Retrospective cohort (PD-1 inhibitors alone or in combination therapy):NA
Prospective cohort 1 (PD-1 inhibitor monotherapy or combined neoadjuvant/conversion therapy):NA
Prospective cohort 2 (PD-1 inhibitor monotherapy or combined adjuvant therapy):NA
Prospective cohort 3 (PD-1 inhibitors alone or in combination with first-line therapy):NA
Prospective cohort 4 (PD-1 inhibitors alone or in combination with second-line or above treatment:NA
Sponsors
Sichuan Cancer Hospital & Institute
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. pathologically or cytologically confirmed esophageal squamous cell carcinoma; 2. received PD-1 inhibitor therapy; 3. the subject voluntarily joined this study and signed an informed consent form
Exclusion criteria
Exclusion criteria: 1. a history of malignancy other than esophageal cancer within 5 years before enrollment, but the risk of metastasis or death is negligible (e.g., expected 5-year overall survival rate > 90%), except for malignancies that are expected to recover after treatment, such as appropriately treated cervical carcinoma in situ, basal or squamous cell skin cancer, localized prostate cancer treated with radical surgery, and ductal carcinoma in situ treated with radical surgery; 2. known or suspected hypersensitivity to PD-1 inhibitors; 3. this study is a real-world study without other special exclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pathologic Complete Response Rate in Cohort 1;Disease-free survival in Cohort 2;Progression Free Survival in Cohort 3/4;Overall Survival;Safty;Patient quality of life and related scales; | — |
Countries
China
Contacts
Public ContactXuefeng Leng
Sichuan Cancer Hospital & Institute
Outcome results
None listed